Trial NCT03184558

View at ClinicalTrials.gov 
Org. Study IDs: BGBC007
Secondary IDs: 2016-003608-30 MK-3475 PN530

Last trial update was posted on 2021-11-09

MeSH Interventions

Pembrolizumab

MeSH Conditions

Breast Neoplasms Inflammatory Breast Neoplasms Triple Negative Breast Neoplasms

Other Conditions

Inflammatory Breast Cancer Stage IV Triple Negative Breast Cancer

Stopping Reasons

Based on planned futility assessment

Limitations And Caveats

None of the participants achieved CR or PR. As there were no responses, the study was terminated. It was planned to terminate the trial in favor of the null hypothesis of futility when 5 or fewer responses were observed in 28 participants.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID